Pfizer-BioNTech and Moderna COVID-19 vaccines for the prevention of coronavirus disease 2019 (COVID-19) in the United States.
You can find these recommendations as well as clinical considerations for managing adverse events below.Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United StatesInterim considerations: Preparing for the potential management of anaphylaxis at COVID-19 vaccination sitesLab tests to collect shortly after severe allergic reaction (e.g., anaphylaxis) following COVID-19 vaccination.
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.